Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.

Garantziotis S.

Br J Cancer. 2011 Feb 1;104(3):542; author reply 543-4. doi: 10.1038/sj.bjc.6606068. Epub 2011 Jan 11. No abstract available.

PMID:
21224852
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.

Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-Deschmann M, Rech-Weichselbraun I, Burghuber C, Pluschnig U, Bartsch R, Graf A, Greil R, Allmaier G, Steger G, Gnant M, Bergmann M, Oehler R.

Br J Cancer. 2010 Oct 12;103(8):1201-8. doi: 10.1038/sj.bjc.6605909. Epub 2010 Sep 28.

PMID:
20877360
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer.

Arnold T, Michlmayr A, Baumann S, Burghuber C, Pluschnig U, Bartsch R, Steger G, Gnant M, Bergmann M, Bachleitner-Hofmann T, Oehler R.

Eur J Clin Invest. 2013 Mar;43(3):286-91. doi: 10.1111/eci.12043. Epub 2013 Jan 25.

PMID:
23410002
[PubMed - indexed for MEDLINE]
4.

Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer.

Taucher S, Rudas M, Mader RM, Gnant M, Sporn E, Dubsky P, Roka S, Bachleitner T, Fitzal F, Kandioler D, Wenzel C, Steger GG, Mittlböck M, Jakesz R.

Breast Cancer Res Treat. 2003 Dec;82(3):207-13.

PMID:
14703068
[PubMed - indexed for MEDLINE]
5.

Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.

Ramaswamy B, Povoski SP, Rhoades C, Allen J, Hauger M, Young D, Burak W, Farrar W, Yee L, Kendra K, Somasundaram S, Orlowski RZ, Shapiro CL.

Breast Cancer Res Treat. 2005 Sep;93(1):67-74.

PMID:
16184461
[PubMed - indexed for MEDLINE]
6.

Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.

Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Toi M.

Jpn J Clin Oncol. 2011 Jul;41(7):867-75. doi: 10.1093/jjco/hyr081.

PMID:
21719750
[PubMed - indexed for MEDLINE]
Free Article
7.

A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.

Yardley DA, Peacock NW, Dickson NR, White MB, Vázquez ER, Foust JT, Grapski R, Hendricks LK, Scott WL, Hainsworth JD.

Clin Breast Cancer. 2010 Jun;10(3):217-23. doi: 10.3816/CBC.2010.n.029.

PMID:
20497920
[PubMed - indexed for MEDLINE]
8.

The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer.

Hirano A, Shimizu T, Imamura H, Watanabe O, Kinoshita J, Okabe T, Kimura K, Kamimura M, Domoto K, Aiba M, Ogawa K.

Anticancer Res. 2006 Jan-Feb;26(1B):581-4.

PMID:
16739324
[PubMed - indexed for MEDLINE]
Free Article
9.

Activity of combination chemotherapy, docetaxel and epirubicin as neoadjuvant therapy for women with breast cancer.

Tfayli A, Holter J, Bova A, Venkatappa S, Bullock S, Dooley W, Ozer H.

Anticancer Res. 2006 Nov-Dec;26(6C):4911-6.

PMID:
17214361
[PubMed - indexed for MEDLINE]
Free Article
10.

Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer.

Espinosa E, Morales S, Borrega P, Casas A, Madroñal C, Machengs I, Illarramendi JA, Lizón J, Moreno JA, Belón J, Janáriz J, de la Puente M, Checa T, Mel JR, González Barón M.

Cancer Chemother Pharmacol. 2004 Dec;54(6):546-52. Epub 2004 Aug 17.

PMID:
15316749
[PubMed - indexed for MEDLINE]
11.

High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.

Chen SC, Chang HK, Lin YC, Hsueh S, Cheung YC, Leung WM, Tsai CS, Lo YF, Tsai HP, Shen SC, Chen MF.

Jpn J Clin Oncol. 2008 Feb;38(2):99-105. doi: 10.1093/jjco/hym172. Epub 2008 Feb 12.

PMID:
18270380
[PubMed - indexed for MEDLINE]
Free Article
12.

[Application of neoadjuvant chemotherapy for operable breast cancer].

Zheng L, Gao HY, Zhang XL.

Nan Fang Yi Ke Da Xue Xue Bao. 2009 Dec;29(12):2510-1. Chinese.

PMID:
20034916
[PubMed - indexed for MEDLINE]
Free Article
13.

[Effects of neoadjuvant chemotherapy of docetaxel combined with and epirubicin or pirarubicin on breast cancer: clinical analysis of 160 cases].

Li XR, Wang JD, Zhang YJ, Kong QL, Ma B, Li J, Zheng YQ, Chen YQ, Jin YC, Li R.

Zhonghua Yi Xue Za Zhi. 2009 Jan 13;89(2):87-90. Chinese.

PMID:
19489268
[PubMed - indexed for MEDLINE]
14.

[Neoadjuvant treatment for locally advanced breast cancer. Comparison of two schemes based on docetaxel-epirubicin vs. 5-fluorouracil-epirubicin-cyclophosphamide].

Cortés-Flores AO, Morgan-Villela G, Castro-Cervantes JM, Vázquez-Camacho G, Fuentes-Orozco C, González-Ojeda A.

Cir Cir. 2008 Jan-Feb;76(1):23-8. Spanish.

PMID:
18492416
[PubMed - indexed for MEDLINE]
15.

Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer.

Heller W, Mazhar D, Ward R, Sinnett HD, Lowdell C, Phillips R, Shousha S, Fayaz A, Palmieri C, Coombes RC.

Oncol Rep. 2007 Jan;17(1):253-9.

PMID:
17143506
[PubMed - indexed for MEDLINE]
16.

[Correlation of expression of Survivin, BCRP and HER-2 genes with therapeutic response of TE regimen neoadjuvant chemotherapy in breast cancer patients].

Li X, Li Y, Yang SE, Ma Y, Wen SJ, Guo L, Guli KZ, Zhao B, Liu W, Hu X.

Zhonghua Zhong Liu Za Zhi. 2011 Dec;33(12):916-20. Chinese.

PMID:
22340101
[PubMed - indexed for MEDLINE]
17.

Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins.

Asakawa H, Koizumi H, Koike A, Takahashi M, Wu W, Iwase H, Fukuda M, Ohta T.

Breast Cancer Res. 2010;12(2):R17. doi: 10.1186/bcr2486. Epub 2010 Mar 5.

PMID:
20205718
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Impact of tumor biology, particularly triple-negative status, on response to pre-operative sequential, dose-dense epirubicin, cyclophosphamide followed by docetaxel in breast cancer.

Warm M, Kates R, Grosse-Onnebrink E, Stoff-Khalili M, Hoopmann M, Mallmann P, Thomas A, Harbeck N.

Anticancer Res. 2010 Oct;30(10):4251-9.

PMID:
21036749
[PubMed - indexed for MEDLINE]
19.

Epirubicin and docetaxel as neoadjuvant treatment of locally advanced breast cancer: a phase II study.

Lombardi D, Scalone S, Crivellari D, Magri MD, La Mura N, Miolo G, Murrone A, Perin T, Coran F, Candiani E, Massarut S, Veronesi A.

Tumori. 2010 Mar-Apr;96(2):229-33.

PMID:
20572578
[PubMed - indexed for MEDLINE]
20.

Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma.

Iwata H, Nakamura S, Toi M, Shin E, Masuda N, Ohno S, Takatsuka Y, Hisamatsu K, Yamazaki K, Kusama M, Kaise H, Sato Y, Kuroi K, Akiyama F, Tsuda H, Kurosumi M; Japan Breast Cancer Research Group.

Breast Cancer. 2005;12(2):99-103.

PMID:
15858439
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk